A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Clear Cell Renal Cell Carcinoma (ccRCC)
- Kidney
- Kidney Cancer
- Renal Cancer
- Renal Cell Cancer Metastatic
- Renal Cell Cancer, Recurrent
- Renal Cell Carcinoma
- Renal Cell Carcinoma (RCC)
- Renal Cell Carcinoma Recurrent
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Belzutifan in combination with cabozantinib administered orally once dailyMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03634540
- Collaborators
- Not Provided
- Investigators
- Study Director: Medical Director Merck Sharp & Dohme Corp.
Get Well Soon